Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection

1The resident microbes of the human gut, collectively termed as gut microbiota, are a highly dynamic and diverse ecosystem, estimated to be composed of trillions of microbial cells, which approximately outnumber by a ratio of 10.1 or roughly equivalent to the number of cells in the human body and encode 500 times more genes than the human genome. Microbial density distribution across the gastrointestinal tract (GIT) is variable from the upper proximal to the distal end of the intestine, mainly dominated by obligate anaerobic bacteria. The normal average healthy gut microbiome is not defined yet; however, it is generally characterized by the presence of high diversity and richness of beneficial bacteria and a lower number of pathogenic bacteria/pathobionts in a healthy state of the host. The normal gut microbial community as a whole behaves as commensals that contribute to the host in a multitude of essential functions; therefore, it is generally referred to as the commensal microbiota. Commonly, the gut microbiota in healthy individuals is populated with five major phyla, namely, Firmicutes, Bacteroidetes, Actinobacteria, Verrucomicrobia, and Proteobacteria, although there is a considerable variation in the diversity and relative abundance at the lower taxonomic level; consequently, the gut microbiota of each individual is unique at the genus and species levels. It has been known for years that the gut microbiota has co-evolved with the host, where the host provides a stable habitat to the microbes. In return, microbes benefit the host with many physiological processes such as food digestion and absorption via production of hydrolytic enzymes and co-factor molecules such as vitamin production, which are critical for the health of the host. Recently, the gut microbiota has been recognized in the more complex biological processes of the host such as metabolism, regulation of the gut barrier function, and immunity development. In addition, the more important function imposed by the gut microbiota is resistance against pathogens, protecting the host from pathogen infections, a phenomenon at present termed as colonization resistance. On the other hand, the altered gut microbiota has also been attributed to a variety of disease pathologies from intestinal functional to systemic metabolic diseases as well as in pathogen infections. The altered gut composition during disease is recognized to have an excessive number of pathogenic bacteria/pathobiont members and a lower number of commensals, indicating that gut microbiota composition may have a role in disease pathogenesis as well as in host susceptibility to disease risk and outcomes; therefore, in the current microbiome research, the gut microbiota is considered as a moderator in host health and disease. Recently, the research on gut microbiome focuses more on the gut microbiota involvement in the pathogenesis of metabolic (obesity, diabetes, NAFLD), chronic immune [inflammatory bowel disease (IBD), arthritis, CNS inflammation], and cancerous diseases and revealed a microbe–host or microbe–environment interaction in disease initiation and progression (which is out of the scope of this review). However, little attention has been given to the role of gut microbiota in pathogen infections to explore the microbe–microbe interaction in the gut microbial community. Growing evidence shows that the expansion of the enteric bacterial infections may be associated with the loss of gut microbiota colonization resistance that prevents the overgrowth of resident pathobionts and the entry of exogenous obligate pathogens under the homeostatic condition.

2Colonization resistance is a phenomenon whereby the normal gut microbiota resists the invasion of the exogenous pathogens and the expansion of the resident pathobionts. This notion is well supported by the induction of severe infections by enteric bacterial pathogens in germ-free or antibiotic-treated mice compared with conventionally raised or untreated control mice upon pathogenic bacteria inoculation as well as with the treatment of bacterial infection models by fecal microbiota transplantation or probiotic gut microbiota species administration, indicating that the normal resident gut microbes play a central role in the prevention of pathogen colonization in the gut to cause intestinal infection. The mechanisms through which the intestinal microbiota provide colonization resistance are complex and have not been fully described; however, many involve direct interactions (such as nutrient competition, niche exclusion, toxic substances, and metabolite production) between bacterial communities (commensals–pathogens/pathobionts), and others act by indirect mechanisms that modulate the host system physiology, particularly the host immune response. Together, these mechanisms impart to colonization resistance against exogenous pathogenic microorganisms and resident pathobionts in the gut environment. However, the high incidence of enteric infections caused by bacterial pathogens indicates that microbiota-mediated colonization resistance can be distressed and turn ineffective. Various factors such as host genetics, diet, and antibiotic usage that can alter the composition and functional capacity of the gut microbial community affect colonization resistance. The disturbance in colonization resistance causes an outgrowth of opportunistic bacterial species that are typically present in low to very high numbers, which can harm the host, such as members of the Enterobacteriaceae family, as well as colonization by pathogenic bacteria, such as Clostridium difficile and Salmonella enterica serovar Typhimurium (S. Typhimurium), thereby rendering opportunities for pathogens to utilize disruption in colonization resistance and colonize the gut, which ultimately leads to cause infection.

3In a healthy host, gut commensals are dominant over pathobionts, while an imbalance is shown in their composition with intestinal functional and infectious diseases, where the pathogenic counterpart dominates over commensals. The outcompeting of pathogens during the normal physiological condition and the expansion of pathogens during disease condition reflect a kind of interaction phenomenon between commensals and pathogenic microbes. During disease, alteration in the homeostatic gut microbiota occurs either due to changes in the host factors (gene expression, immunity such as inflammation) or environmental factors (diet or antibiotic). As a result, alterations occur in the physiological environment (pH) and in the metabolic and nutritional landscape of the intestine, which may favor the growth of the pathogenic microbes and inhibit commensals that may increase the risk of pathogen colonization and infections. The altered gut microbial community dominated with pathogenic bacteria further aggravates the gut condition by inducing intestinal inflammation, which causes further enhancement in pathogen growth, virulence, and survival maintenance. The growing power of innovative computational analysis, multi-omics data analysis technologies (metagenomics, transcriptomics, and metabolomics), and the use of more conventional study approaches expanded our knowledge on the gut microbiota interactions and their impact on the metabolic and physiological landscape of the intestine in relevance to the severity and outcome of gastrointestinal infections.

4With the recent advancements in the field of microbiome studies, the current research is focused on the associations between the microbiota, host, and pathogenic bacteria to unravel how the composition of the microbiota can offer either resistance or assistance to the invading pathogenic/pathobiont species. The majority of these studies were conducted in the GIT, in which associations between the host and microbes are of paramount importance. The gut microbiota, commensals, and pathogenic bacteria are adapted to the gut environment and establish complex ecological networks within the community and with the host to acquire their needs such as nutrients and maintain the normal gut microbial composition and survival. The gut microbial community establishes symbiotic relationships with commensal members to survive and remain dominant over pathogens. For example, in the gut microbiota, certain commensal species such as Lactobacillus spp. and Eubacterium dolichum are unable to manufacture certain amino acids and thus obtain these critical molecules from the host gut lumen contents or habitat. Likewise, methanogens acquire their energy from waste products such as hydrogen molecules that are produced by other obligate anaerobes. Conversely, the gut microbiota adapted a negative antagonistic relationship with pathogens/pathobionts to suppress their growth either directly via the production of bacteriostatic/bactericidal substances against pathogens or indirectly where commensal bacteria communicate with the host via their cell surface antigenic molecules such as lipopolysaccharides (LPS) and peptidoglycans (PGNs) and produce metabolites which either promote the host gut barrier physiology to restrain pathogen/gut microbiota translocation into the systemic circulation or activate the host mucosal/systemic immunity to prevent pathogen colonization in the gut. Commensal bacteria also adapted several other ways to restrain pathogen colonization, such as competing for nutrients, occupying a specific niche, and changing the gut physiological environment. On the other hand, pathogenic microbes or pathobionts also evolve direct or indirect strategies like commensals to overcome commensal-mediated colonization resistance and expand their growth to cause infection, which underlies the discussion of microbe–microbe and microbe–host interaction.

5Consequently, the gut microbiota community interactions in the intestine can be categorized into three major themes, namely, microbial–host, microbial–environmental, and microbial–microbial interactions, that dictate the distribution of individual microbial species membership and abundance across the GIT, which may lead to interindividual gut microbiota differences in composition and density as well as to variable susceptibility to diseases between individuals. Various previous studies reported the relevance of the gut microbiota in host health outcomes and their disruption with multiple chronic metabolic and inflammatory diseases, where microbial–host, microbial–environmental, and/or microbial–microbial interactions were altered, but limited work is available on the gut microbiota in the relevance of resistance to pathogen colonization and its disruption impact on pathogenic infections.

6The current review article focuses on; gut microbiota interaction; microbe–microbe; microbe–host interactions in pathogen colonization resistance and infection prevention. The gut microbiota interactions within the community and host form a triangular network, as summarized in Figure 1. Therefore, any disruption in the typical regular gut microbiota composition may interrupt this triangular network of the gut microbe–microbe interaction within the community and microbe–host interaction, yielding a bloom in pathogenic/pathobiont bacteria population and their associated infections. In this review, we make an effort to review the available literature on the perturbation of the gut microbial community from the perspective of gut microbial colonization resistance and pathogenic bacteria-associated infectious diseases and their underlying mechanism.

7As the majority of the mechanistic studies have been conducted in S. Typhimurium, enterohaemorrhagic Escherichia coli (EHEC), and C. difficile to investigate these interactions; therefore, this review covers these pathogenic organisms more extensively than others.

8Among the gut microbiota regulating factors, diet is one of the major determinants that define the composition and distribution of the microbiota in the different compartments of the GIT. The mammalian host is colonized with a simple structured gut microbiota immediately after birth; however, with age, as the diet changes from breastfeeding to fiber-rich nutrition, the gut microbial structure and composition is altered dramatically. The simple sugar molecules and amino acids are rich in the small intestine, readily absorbed by the host cells; thus, carbon as an energy source is not or less available for microbes to use in that region. In contrast, the complex polysaccharide molecules derived from plant or animal sources are indigestible by the host and move to the colon. So, energy sources for bacterial growth are substantially altered across the GIT compartment. As a result, the gut microbiota composition and density are also variable along with the lower GIT from the upper small intestine down to the lower end of the colon. The upper part of the colon is populated with a high density of Proteobacteria and Lactobacillales, and their number is reduced in the large intestine colon, implying that Proteobacteria, such as Escherichia coli, cannot digest complex carbohydrates and cannot use them as energy sources. In contrast, the colon is colonized with a high density of Bacteroides and Clostridiales, implying that these bacteria may have hydrolytic digestive enzymes and can use the complex polysaccharide polymers as an energy source. Consequently, the abundance of Proteobacteria and Lactobacillales is much lower in the colon, whereas Bacteroides and Clostridiales are the dominant populations in the large intestine. The given literature suggests that diet content can significantly influence the relative abundance of microbial taxa and their distribution in the gut. Thus, nutrient content works as a major driving force in defining the microbial community structure in the intestine. In addition, it also indicates that usually in fiber-rich diet consumption, the density of the beneficial bacterial is dominant over pathobiont or pathogen counterparts such as E. coli. Furthermore, diet has been acknowledged for its profound effect on the gut microbiota composition to host physiology, immunity, and susceptibility to infectious diseases. Dietary choices have successfully affected the susceptibility to enterohemorrhagic E. coli (EHEC) serotype O157:H7 (E. coli O157:H7) infection in mice, where the high fiber diet (HFD)-fed mice had shown higher E. coli O157:H7 colonization level and more severe infection than in mice fed with the low fiber diet (LFD). The administration of diet with phytonutrient supplementation expanded the growth of beneficial bacterial Clostridia species that protect mice colonization by the pathogen Citrobacter rodentium [C. rodentium, a mouse bacterium that is used extensively in mouse models as a surrogate for the human enteric pathogens EHEC and EPEC (enteropathogenic E. coli)]. However, the discrepancy in microbial diversity and its distribution among individuals is multifactorial and cannot be described by a single factor alone. For example, Bifidobacteria, a commensal bacterium, abundantly colonizes the human intestine, affecting its response to pathogen attack. Germ-free or antibiotic-treated mice challenged with pathogenic species showed severe enteric infection than wild-type mice, indicating that the interaction of gut-resident microbes and pathogens may affect disease outcomes. This explanation implies that the gut microbiota diversity and density distribution may also be affected by microbe–microbe and microbe–host interactions. Therefore, additional ecological analyses of intracommensal interactions and better characterization of the metabolic activities of individual bacteria are required to completely understand the microbial ecosystem in the intestine.

9The theme is that gut microbiota has an effect on the risk and course of the host enteric diseases either by resistance or assistance to the colonization of the host by pathogenic microbial species. Several preclinical animal modeling studies have shown that the microbiota can promote resistance to colonization by pathogenic species. The germ-free and antibiotic-treated mice experienced a more severe enteric infection and showed high susceptibility to enteric pathogens such as S. Typhimurium, Shigella flexneri, Listeria monocytogenes, and C. rodentium, than conventionalized wild-type or specific pathogen-free (SPF) mice. Similarly, some microbiota has led to the expansion or enhanced the virulence of the pathogenic microbial population and results in severe infection. The impact of the gut microbiota on pathogen colonization resistance is best explained by a microbial transfer experiment, where transplantation of microbiota from a strain of mice infected with C. rodentium induced a similar susceptibility in mice that were resistant before, and the transplantation of microbiota from an insusceptible animal led to resistance against pathogen infection in animals which were highly susceptible before. In addition, the concern is how the differences in the gut microbiota composition affect susceptibility to pathogen infection. A human clinical survey study further reinforces this idea. For example, a Swedish study reported that susceptibility to Campylobacter jejuni infection was shown to be dependent on the gut microbiota species composition. Individuals with higher diversity and richness of microbiota and with a high count of bacterial species from the genera Dorea and Coprococcus showed significant resistance to C. jejuni infection. By contrast, those individuals who had a lower microbial diversity and with a low count of bacterial species from the genera Dorea and Coprococcus showed high susceptibility to infection with C. jejuni. The treatment of pathogen infection in animal models with gut microbiota transfer from a healthy donor, with probiotic intervention, or with microbial metabolite administration further validates the gut microbiota relevance to pathogen colonization resistance and prevention of pathogen-associated infections.

10In the gut microbiota, both the commensals and pathogens require a common source of energy, habitat, and nutrients, for which they must struggle to best adapt in the intestine of the host, to colonize and grow. Therefore, they must evolve certain mechanisms to best utilize these resources and outcompete each other. Generally, commensal bacteria regulate the population and activity of the pathogenic bacteria either by direct or indirect ways to maintain the normal healthy gut microbial composition while using the axes of microbe–microbe and microbe–host interactions, shown in Figure 1. In the direct mechanism to prohibit pathogen colonization by commensals, the commensals mediate colonization resistance by killing the pathogens or reducing their growth by producing toxic chemical substances such as bacteriocins, secondary bile acids, and proteinaceous toxins, changing the gut physiological environment (pH alteration) and nutrient competition as well as through specific metabolite production. On the other hand, in the indirect mechanism, the commensals in the gut microbiota combat the pathogens mainly via induction of the host immune response against pathogens. The overall mechanisms of commensal colonization resistance are shown in Figures 2 and 3.

11Optimum pH is highly critical for the growth of most enteropathogenic bacterial species such as Bacillus cereus, E. coli, and enterotoxigenic bacteria. To downregulate the pathogenic bacterial growth, the commensal bacteria evolve certain strategies that alter the gut local physiological environment by modulating the pH and that prevent pathogen colonization and reduce the risk of intestinal infectious diseases. Certain commensal bacteria produce short-chain fatty acids (SCFAs), i.e., butyric acid, propionic acid, and acetic acid, major metabolic products of most gut microbial fermentation, which modulates the gut pH and prevents the proliferation of certain intestinal pathogenic microbe populations. In a mouse model study of enteric pathogen S. Typhimurium infection, the Bacteroides species showed resistance against S. Typhimurium colonization by changing the pH of the gut through the production of propionate that limits its growth. The probiotic species Bifidobacterium has blocked the pathogenic E. coli growth by reducing its environment pH. In addition, commensals also produce certain metabolites that can directly inhibit specific microbial members of the same or related bacterial species. For example, bacteriocins from E. coli directly inhibit the growth of related pathogen EHEC. Although commensal bacteria resist pathogen colonization and reduce the risk of pathogens associated with intestinal infections via modulating the gut pH, however the underlying molecular mechanism of the phenomenon is partially or completely unexplored.

12The preferential consumption of nutrients by commensals, which are required by pathogenic bacteria for their growth, is an alternative strategy of the commensal bacterial community to outcompete the pathogenic microbes. For example, commensal E. coli with EHEC competes for amino acids, organic acids, and other nutrients. By consuming the commonly available limited nutrient resources, the commensal community causes the starvation of the competing pathogenic bacteria. Commensal bacteria also produce certain toxic chemicals which affect the pathogen virulence and compromise their proliferation. For example, butyrate, a short-chain fatty acid, downregulates the expression of several virulence genes, including those of the secretion system type 3 proteins (SST3) in the enteropathogenic species, i.e., Salmonella Enteritidis and S. Typhimurium. Similarly, fucose, a host mucin-derived component, is generated as a fermentation product by a commensal bacterium Bacteroides thetaiotaomicron, which possesses fucosidase activity that affects the expression of the virulent factor Ler that works as a key regulator of the locus of enterocyte effacement (LEE) genes in EHEC. Thus, commensals not only modulate and affect the pathogen virulence directly via the production of metabolites but also suppress the pathogen virulence genes by altering the physiological condition required for the virulence activity of the pathogens. For example, high oxygen tension is required for the virulent gene expression of S. flexneri to produce the Shiga toxin. In response, the commensal facultative anaerobic bacteria such as E. coli, a member of the Enterobacteriaceae family, consume the available residual oxygen, leading to the partial expression of the S. flexneri virulent factors in the gut lumen.

13Gut commensals also mediate pathogen colonization resistance to prevent pathogen infection indirectly by enhancing gut immunity, including promoting the functionality of the gut barriers and innate immune responses. The epithelium layer/barrier is the first line of defense against any invading pathogen. The concept that gut epithelial barriers are functionally regulated by the gut microbiota is primarily supported by indirect evidence. For example, the germ-free and mice deficient with proteins involved in microbial recognition, such as NOD2 and MYD88, had shown with impaired production of antimicrobial peptides, particularly by Paneth cells of the small intestine. MYD88-deficient or Paneth cell-deficient mice have shown abnormal gut barrier function and a high level of the pathogenic bacterial load inside the gut mucosa (bacterial translocation) due to their inability to produce sufficient and specific antimicrobial peptides to prevent pathogen colonization. In addition, antimicrobial peptides not only prevent pathogen infections by direct killing but also limit pathogen bacteria colonization. For example, mice deficient in MYD88 adaptor protein or Paneth cell have shown higher mucosa-associated bacterial load in the small intestine than wild-type littermates.

14Additionally, the intestinal microbiota not only enhances the gut barrier function but also promotes host innate immunity to resist enteric pathogen infection. IL-1β is a cytokine typically produced during active infection that is critical for enteric pathogen elimination. The gut microbiota has been recognized with homeostatic level production of pro-IL-1β in the intestine-resident macrophages. The production of pro-IL-1β from the resident gut macrophages is MYD88 dependent, which is regulated by the gut microbiota. Thus, the gut microbiota regulates the priming of the macrophages to rapidly respond to the invading pathogens by converting pro-IL-1β into mature active IL-1β to prevent its colonization. Gut microbiota can also induce host immunity via an MYD88-independent manner. For example, colonization of germ-free mice with commensal bacteria produces the T helper 17 (Th17) cell in the intestinal tissue, which confers resistance to enteric pathogen infection, such as C. rodentium, which is independent of microbial recognition signaling molecules such as MYD88, TRIF, and RIP2. Interleukin 17-producing Th17 cells and a certain subset of dendritic cells are a group of type 3 innate lymphoid cells (ILC3), producing interleukin 22 (IL-22), which is involved in the upregulation of the gut barrier protein REGIIIγ. IL-22-mediated production of REGIIIγ by the intestinal epithelium is protective against enteric infection by C. rodentium. The role of the commensal bacteria for the production of REGIIIγ and elimination of pathogenic bacteria has been more specifically justified by the administration of the bacterial-associated antigenic molecule lipopolysaccharide (LPS) or bacterial flagellin that upregulated REGIIIγ and enhanced the eradication of Enterococcus species, known as vancomycin-resistant Enterococcus (VRE). In addition to the production of antimicrobial peptides, interleukins, the gut microbiota signaling is likely through MYD88 which may also enhance the gut barrier function via secretory antibody immunoglobulin A (IgA) production from intestinal epithelial cells. Secretory IgA mediates pathogen resistance by binding to specific microbial antigens and neutralizes pathogen activity, thus preventing pathogen colonization to cause infection. In host mucosal immunity, antimicrobial peptides and IgA are also involved in gut microbiota shaping; however, the composition of the gut microbiota is regulated by multiple factors; therefore, its remain unclear that these two factors alone are the main determinants for pathogen resistance.

15Furthermore, the role of commensals taking advantage of the host immune response and mediating pathogen colonization resistance is clearly visible from studying pathogen infections in animal models. For example, a mouse model of sepsis induced with human sepsis-associated bacterial pathogen was rescued with fecal microbiota transplant (FMT) by enhancing pathogen clearance via restoration of the host systemic immunity. This effect of FMT is linked to the upregulation of butyrate-producing Bacteroidetes, which increased the expression of interferon (IFN) regulatory factor 3 and alleviated the disease pathology. The study suggested that FMT may be a possible therapeutic option in sepsis, related to the host immunosuppression. A study on a mouse model of parasitic protozoa reported that colonization of Clostridium scindens protects from Entamoeba histolytica colitis, where the gut microbiota species cross-talk with bone marrow and regulate susceptibility to amebiasis via innate immunity activation. The protection mechanism of the intestinal bacterium C. scindens against E. histolytica is dependent on bile salt metabolism. The bile salt-derived metabolite deoxycholate activates the host bone marrow epigenetically and increases the immune response by inducing the immune cells granulocyte monocyte progenitors (GMPs) and neutrophils into the gut that prevent the colonization of E. histolytica. The gut microbiome was also found to protect against virus infection in a mouse model by modulating the host innate immunity. The intestinal bacterium C. scindens has restricted the alphavirus (CHIKV) infection and dissemination in a mouse model by restoring the antiviral immune response type I IFN signaling through its associated metabolite deoxycholic acid production. Similarly, Clostridium orbiscindens, a human intestinal bacterium, and its derived metabolite desaminotyrosine (DAT), has rescued mice infected with influenza virus through modulation of type I IFN signaling. The probiotic Bacillus bacterial species have been found to eliminate Staphylococcus aureus infection by inhibiting/reducing its intestinal colonization through signaling interference (quorum sensing) of S. aureus. Quorum sensing is a signaling mechanism through which bacteria manage their gene expression and metabolism according to their population density. Candida albicans colonization in the GIT has been restricted by commensal anaerobic bacteria—specifically Firmicutes (clostridial clusters IV and XIVa) and Bacteroidetes—through induction of HIF-1α and LL-37 that activated innate immunity effectors in the gut. Corynebacterium mastitidis, an ocular commensal, protects the cornea from pathogenic C. albicans and Pseudomonas aeruginosa infection by inducing the IL-17 production from resident mucosal gd T cells. The gut microbiota is also recognized in the protection from malaria parasite transmission by eliciting a specific immune response. In addition, the gut microbiota mediates systemic immune effects via immunoglobulin G (IgG) production that safeguard against systemic infections by S. Typhimurium and E. coli. Enterococcus faecium, a human commensal bacterium, protects against S. Typhimurium infection in mice via the production of antimicrobial peptides through an associated unique peptidoglycan hydrolase secreted antigen A (SagA). SagA interacts with the pattern recognition receptors found in the host gut epithelial cells and elicits an innate immune response against the Salmonella pathogen. This brief discussion justifies that commensal bacteria restrain pathogen growth using the host immunity via a variety of mechanisms.

16Disruption of the gut microbiota, most commonly associated with antibiotic usage, has been known for its rapid, dramatic, and sometimes everlasting effect on the gut microbiota composition and activity and can alter the microbial taxonomic and functional profile. It decreases the diversity of commensal bacteria, which compromises resistance to colonization by incoming invading pathogenic bacteria or by existing pathobiont expansion. The loss of commensal-mediated colonization resistance against pathogens by antibiotics increases the individual susceptibility to enteric pathogen infections such as by S. Typhimurium and EHEC and most notably leads to substantial growth in the abundance of C. difficile, followed by a severe intestinal inflammation. S. Typhimurium, EHEC, and C. difficile are typically the pathogenic bacterial species used for most mechanistic studies investigating such interactions. C. difficile is a leading nosocomial infectious disease associated with diarrhea and colitis. Typically in the intestine of a healthy human, C. difficile growth is suppressed by commensals, thus controlling its presence and number; however, a substantial increase was seen after treatment with broad-spectrum antibiotics in hospitalized patients, followed by an acute intestinal inflammation. Like in human, the mouse C. difficile infection model has also reported that C. difficile could not colonize and induce intestinal inflammation in wild-type mice, whereas antibiotic therapy enhanced the incidence of C. difficile infection, which did not disseminate systemically but caused gross damage to the intestinal epithelial barrier via production of their associated toxins TcdA and TcdB. In consequence, the toxin-mediated epithelial barrier disruption has led to the systemic dissemination of the gut microbial species, which may induce lethal septic shock. Thus, for C. difficile to induce colitis, the use of antibiotics is one of the most important risk factors. Similarly, S. Typhimurium is another bacterial enteric pathogen that is commonly associated with food ingestion and poorly colonizes the mouse gut during the normal physiological condition due to the presence of the resident commensal microbial community. However, when the resident gut microbial community is disrupted with antibiotic use, or the recipient mice have low complexity and reduced diversity of the gut microbiota, the pathogen can freely proliferate and induce inflammation. In addition, an altered gut microbial community structure may also facilitate the proliferation and outgrowth of the potentially harmful pathobionts of the intestinal indigenous bacteria. For example, E. coli is an avirulent bacteria; normally, its growth is suppressed by the gut commensal microbes; however, its overgrowth and accumulation occur with antibiotic use and can disseminate across the gut mucosa systemically following intestinal epithelial injury by a stimulus such as dextran sulfate sodium (DSS), thereby inducing intestinal inflammation in mouse. Furthermore, VRE causing sepsis in immunocompromised individuals has been associated with antibiotic treatment.

17Normally, commensal gut bacteria regulate the harmful subset of bacteria, including VRE, through induction of innate immunity such as the production of antimicrobial peptides, for example, REGIIIγ, particularly more important for bacterial killing, which has been found with the eradication of VRE. However, a recent study suggested that a specific intestinal bacterial consortium facilitates the clearance of the VRE species, which works independently of the host innate immune pathways, such as MYD88 signaling. Although the specific mechanism is unknown, it may be related to the direct mechanism such as competition for the common limited source of nutrition or the commensal gut microbiota mediates VRE eradication via the indirect mechanism (immune response induction), or both mechanisms depend on different regions of the intestine. For example, in the small intestine, the production of antimicrobial proteins might be a primary mechanism for clearance of VRE, whereas direct killing/inhibition by a specific microbial population may be a primary mechanism in the colon.

18As described earlier, multiple strategies have been developed by the commensal gut microbiota that mediates pathogen colonization resistance to prevent pathogen infection. Similarly, on the other hand, pathogens also evolved counter mechanisms to escape from these regulatory mechanisms and dominate over commensals and cause infection. For instance, to counteract nutrient competition by commensals, certain pathogens have developed strategies to use alternative nutrients or to utilize the commonly available nutritional resources more efficiently (see Figures 2, 3 ).

19In the human gut, the simple sugars are absorbed in the small intestine, and the complex polysaccharides and host glycan are available as energy-rich sources in the colon; therefore, the most abundant microbiota are those that are able to use these undigested complex polymers as a nutrient source in the colon. The gut epithelium mucosal layers, which are known as mucin, act as protective barriers, rich in sugar components, such as sialic acid, fucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, and mannose. These sugar molecules are metabolized by saccharolytic members of the gut bacterial community, such as members of the Bacteroidales, making them available as an energy source for those members that are unable to harvest these sugars, and the pathogenic bacteria can also utilize these available nutrients for the proliferation of their growth. Several previous studies have investigated these syntrophic interactions in the gut microbiota members of Bacteriodales, where B. thetaiotaomicron is used as a model species. B. thetaiotaomicron harbors multiple hydrolytic enzymes and has the ability to catabolize host glycan multiple components. For example, B. thetaiotaomicron has sialidase activity to release the sugar component sialic acid from the gut epithelial mucins but lacks the capability to utilize it; however, the bacterium gains access to the underneath glucans to use it as an energy source while releasing sialic acid. The release of sialic acid by the bacterium B. thetaiotaomicron enhances its availability in the colon, which can be used by pathogenic bacteria such as C. difficile and S. Typhimurium as an energy source, which provides them a growth advantage over commensals. Therefore, microbiota and pathogenic bacteria that use sialic acid as their energy source depend on the presence and activity of B. thetaiotaomicron, as reported that B. thetaiotaomicron mutants that have no sialidase activity, are failed to give a growth advantage to these two pathogenic bacteria i.e. C. difficile and S. Typhimurium. Similarly, B. thetaiotaomicron also releases sugar fucose from the epithelial mucus layer, results in an increase in the availability of this sugar in the gut lumen, which can be used as an energy source by S. Typhimurium. More importantly, B. thetaiotaomicron has shown enhancement in the fucosylation of the mucosal glycan in monoassociated germ-free mice. The gut-resident microbiotas almost occupy the entire lumen or adhere to the outer mucus layer of the intestinal epithelium, and the pathogenic bacteria such as EHEC compete to achieve a unique niche by adhering to the gut epithelial enterocytes; therefore, the pathogenic bacterium EHEC must struggle for nutrients to successfully outcompete the commensal microbiota. EHEC has the ability to colonize the intestine due to the freely available simple sugar molecules that can be used by the commensal E. coli as well. Commensal E. coli has multiple strains with shared nutritional requirements with EHEC; hence, the intestinal colonization of the mouse by EHEC can interfere with E. coli. A mouse model of EHEC treated with streptomycin while having three distinct strains of commensal E. coli was used to examine the differential sugar requirements for the successful intestinal colonization of the mouse. EHEC has successfully colonized in the mouse model that was only precolonized with at least one commensal E. coli strain but failed to colonize in mice that were precolonized with all three commensal E. coli strains. In normal circumstances, EHEC can only utilize monosaccharides and disaccharides, which can also be used by the commensal bacteria E. coli; thus, commensal E. coli is the only main competitor of EHEC that utilizes the simple sugar fucose as a preferential source of carbon in the mammalian intestine. To counteract and compete E. coli, EHEC has employed certain catabolic pathways to metabolize several distinct alternative sources of sugar simultaneously, such as hexuronate, glucuronate, galacturonate, and sucrose during colonization of the gut, which is not employed by the gut commensal E. coli, thus resulting in the expansion of EHEC growth. The loss of this polymetabolic capability has an additive effect on intestinal colonization of EHEC, whereas this event is not observed in commensal E. coli, which predicts that E. coli utilizes freely available sugar molecules in a stepwise manner. Therefore, EHEC and commensal E. coli have differences in the colonization of the mammalian intestine due to their difference in metabolic strategy for energy extraction and the use of nutrients. In contrast, B. thetaiotaomicron has a diverse source of nutrients and does not need to compete with EHEC such as C. rodentium, because it can use polysaccharides. So, when a diet contains both monosaccharides and polysaccharides, then B. thetaiotaomicron prefers to use polysaccharides instead of competing for monosaccharides, and as a result, C. rodentium is not cleared by B. thetaiotaomicron. However, B. thetaiotaomicron is forced to compete with C. rodentium for monosaccharides and clears it from the mouse intestine in case when a diet contains only monosaccharides. In addition, another study reported that although C. rodentium exhibits a similar nutritional and metabolic profile as the non-pathogenic commensal E. coli, however, it resides in a unique niche on the intestinal epithelium surface, where commensals cannot reside normally, because C. rodentium expresses a distinct adhesion molecule known as intimin, encoded by LEE genes; therefore, C. rodentium lives in a different environmental region and has no need to compete for nutrients with commensals.

20Moreover, ethanolamine is an abundant source of carbon and of nitrogen release as a by-product into the intestine lumen during the intestinal epithelial cell turnover that can be used by several pathogenic bacterial species as a pathogen-specific nutrient, while it cannot be used by the majority of the gut commensal bacteria. Pathogenic bacteria, particularly of food origin, are specially adapted to use it, such as by EHEC, due to having the eut operon in its genome for ethanolamine metabolism. In contrast, non-pathogenic commensal E. coli do not possess the eut operon and cannot utilize ethanolamine as a nutrient. Consequently, the bacteria S. Typhimurium, EHEC, and L. monocytogenes have favorable growth over the commensals in the intestine due to their capability to metabolize ethanolamine as an energy source. Moreover, some pathogenic bacteria use effective mechanisms for nutrient uptake and consume the available common sources of energy more efficiently than commensals. For example, many bacteria produce siderophore, an iron-chelating small molecule, to acquire iron in sufficient quantity, which is an essential component for bacterial growth. In response, lipocalin-2 (Lcn2) is produced by host cells that block the 2,3-dihydroxy benzoate-based siderophore enterobactin (Ent) in the commensal E. coli, thereby stopping the iron acquisition and growth proliferation of the commensal E. coli. In contrast, pathogenic bacteria such as pathogenic E. coli, S. Typhimurium, and Klebsiella pneumoniae possess a variant form of Ent, referred to as salmochelins, which escape the host cell Lcn2-mediated inhibition of salmochelin, leading to a growth advantage of the harmful bacteria over commensals. Thus, pathogenic gut microbes evolve different potential mechanisms to circumvent commensal-mediated colonization resistance and allow their establishment in the gut to colonize and cause infection.

21Apart from using nutrients as an energy source, pathogenic microbes use the lumen nutrient content or gut microbiota-derived molecules as metabolic signals of the host intestinal environment to adjust their activity accordingly. For example, EHEC uses fucose as a signaling molecule to regulate their metabolism and gene expression related to virulence and metabolic stimulus. EHEC possesses a fucose-sensing signaling transduction system, which is developed through the accumulation of pathogenicity island genes (virulence genes) that are acquired horizontally. It is a unique signaling system in EHEC and C. rodentium. In brief, the fucose-sensing signaling transduction system is basically composed of FusK and FusR components. FusK is a membrane-bounded histidine sensor kinase that undergoes autophosphorylation in the presence of fucose; later on, FusK transfers its phosphate to FusR. FusR is a response regulator of the fucose signaling system and acts as a transcription factor. Upon phosphorylation, FusR is activated, which causes the repression of the genes associated with fucose utilization in EHEC, thereby helping EHEC to avoid competing with commensal E. coli for this nutrient. In addition, EHEC avoids the unnecessary use of energy using FusR, which causes the repression of the genes associated with encoding the virulence machinery of the EHEC, which is a syringe-like apparatus also known as a type III secretion system (T3SS), which is used by bacteria EHEC to adhere to the host enterocytes and highjack the function of these cells. Therefore, EHEC utilizes fucose, a host-derived gut microbiota metabolic product, as a signal molecule that senses the intestinal lumen environment and adjusts its metabolism and virulence accordingly. Similarly, ethanolamine can also be used as a signal molecule by pathogenic bacteria such as EHEC and S. Typhimurium for the activation of their virulent gene expression. In addition to ethanolamine, S. Typhimurium exploits gut microbiota-derived hydrogen as a source of energy for its growth expansion at the initial stage of infection. Furthermore, EHEC and C. rodentium produce mucinases, which cleave the protein backbone of mucin-type glycoproteins, which are the main component of the host mucosa epithelial layer; by degrading this, these bacteria can access the lining of the epithelium. The expression of these enzymes is enhanced with B. thetaiotaomicron-produced metabolites. Actually, mucus is one of the major available sources of sugar in the gut colon, which is colonized by the bacteria EHEC and C. rodentium. As a consequence of the mucus layer devastation, a nutrient-poor environment is created near the epithelium, which is referred to as the gluconeogenic environment. Mice colonization with B. thetaiotaomicron profoundly changed the metabolic profile of the mouse colon by raising the level of organic acids such as succinate. Moreover, a gluconeogenic environment is also characterized by an elevated level of several other metabolites such as lactate and glycerate. EHEC and C. rodentium sense this gluconeogenic and succinate-rich environment of the colon through its transcriptional regulator Cra. Upon confirmation that they have gained access to the gut epithelium lining, these bacteria induce the expression of their secretory systems T3SSs. Therefore, EHEC exploits the metabolic cues of the intestine lumen, which are produced by the microbiota, more specifically by B. thetaiotaomicron, and regulates its metabolism and virulence. Other pathogenic bacteria also use microbiota-produced metabolites as signaling molecules to adjust their metabolism and gene expression. For example, C. difficile utilizes the gut microbiota-produced succinate and transforms it into butyrate, thus gaining a growth advantage in vivo. In contrast, C. difficile mutant population is unable to catabolize succinate and fails to expand their growth in the gut due to the presence of B. thetaiotaomicron. More commonly, the gut microbiota produces SCFAs, which are more important metabolites that determine the interactions between the commensal microbiota and pathogenic bacteria in the intestine. The same as diet, the distribution, concentration, and composition of the SCFAs are distinct along with the different compartments of the intestine, and this difference may develop a different physiological environment, which may be sensed by the pathogenic bacteria signaling system as an environmental signal of the colon distinct region, thereby helping in the recognition of the niche by pathogenic bacteria. The most abundant SCFAs that are present in the gut are propionate, acetate, and butyrate. For example, the ileum part of the intestine is generally rich in acetate, having a concentration of 30 mM. This concentration of acetate enhances the expression of pathogenicity island 1 (SPI-1)-encoded T3SS (T3SS-1) of S. Typhimurium, which is involved in bacterium invasion in the host gut; therefore, the ileum region of the intestine is preferably colonized by S. Typhimurium. Conversely, the propionate and butyrate concentrations of 70 and 20 mM in the colon, respectively, repress the expression of T3SS-1-related genes, indicating that propionate and butyrate have an effect on the regulatory cascade of the T3SS-1 at various levels; however, the underlying mechanism of this regulation has not been unraveled yet. In the case of EHEC, the butyrate concentration found in the colon promotes the EHEC T3SS expression via post transcriptional activation of the Lrp, which is a transcriptional regulator in EHEC. Conversely, the exposure of the EHEC to the concentrations of acetate and propionate in the small intestine has not significantly affected the expression of genes related to the virulence of EHEC or EHEC T3SS. Diet is an important moderator of the healthy microbiome and has been known for its profound effect on the microbiota composition and SCFA concentration in the intestine. A fiber-rich diet leads to a higher production of butyrate by the intestinal microbiota, which enhances the expression of the host’s globotriaosylceramide, an enterocyte receptor for the Shiga toxin that is produced by EHEC. In EHEC outbreaks, Shiga toxin is often associated with high morbidity and mortality and can lead to the development of a severe urinary tract complication known as hemolytic uremic syndrome (HUS). Consequently, animals using a fiber-rich diet may show more susceptibility to Shiga toxin than those using a fiber-poor or low-fiber diet and may develop a more severe disease. In contrast, a high level of acetate has been identified with protection of the host from toxin-mediated disease. For example, certain species of commensal Bifidobacteria have been found to raise the level of acetate in the gut, which in turn helped in the prevention of Shiga toxin-mediated toxicity dissemination from the colon to the systemic circulation by promoting the intestinal epithelium barrier integrity and function. Thus, pathogenic bacteria require the exploitation of the microbiota-derived molecules both as signals and nutrients for successful colonization to cause infection in a host.

22Using the host immune response is another strategy used by pathogenic bacteria to have growth advantage over commensals, thereby inducing intestinal inflammation that prevents the survival of commensals in the gut environment. Most of the pathogenic gut microbes produce virulent factors such as toxins that induce gut inflammation. Pathogen-mediated intestinal inflammation or diarrhea substantially alters the balance of the gut microbial community, where the population of commensal microbiota decreases, which in turn increases the number and proliferation of existing or invading pathogens over commensals, thereby increasing the chance of pathogen colonization because of less competition. A marked increase in C. rodentium growth was seen in the intestine of a DSS-induced mouse model of colitis; however, virulence factors are necessary for the colonization and proliferation of this bacterium, because the ler (a virulent factor gene) mutant has failed to get a survival advantage from DSS-induced intestinal inflammation to enhance their growth. Similarly, S. Typhimurium also acquires growth advantage from self-induced intestinal inflammation. Normally, commensal microbiota releases an abundant amount of hydrogen sulfide (H2S), which is converted into thiosulfate by the host mucosa epithelium to avoid H2S-mediated host cell toxicity. During S. Typhimurium infection, a high level of recruited neutrophils and macrophages produces a huge pool of oxygen species that convert into tetrathionate. Unlike commensal bacterial species, S. Typhimurium possesses the operon ttrSR ttrBCA that allows consuming resulting in a growth advantage of S. Typhimurium over commensal bacteria in the intestine during colitis. Furthermore, augments the growth of S. Typhimurium on ethanolamine. Likewise, other enteropathogenic bacteria including EHEC, EPEC, and C. rodentium may also benefit from intestinal inflammation. During intestinal inflammation, the gut mucosa tissue, migrated neutrophils, and macrophages having inducible nitric oxide synthetase enhance the production of nitrate (NO3−); as a result, the level of nitrate (NO3−) is raised in the intestine. The majority of the gut commensal microbiota are obligate anaerobes such as Bacteroidetes or Firmicutes that cannot use nitrate (NO3−) as an electron acceptor, but pathogenic bacteria, which are facultative anaerobes such as E. coli, express nitrate reductase enzymes and can use nitrate (NO3−) as an energy source for their growth, thus leading to a growth and survival advantage over anaerobic commensals in the inflamed intestine. Furthermore, the inflammatory environment of the host gut acts as a signal to trigger and enhance the expression of virulence factors and facilitate pathogen colonization and proliferation. For example, P. aeruginosa, a human opportunistic bacterial pathogen, causes nosocomial infection, which uses its outer membrane surface protein OprF and binds to the host immune factor interferon-γ (IFN-γ), thus inducing a quorum sensing-dependent virulence determinant type I P. aeruginosa (PA-I) lectin. This is how pathogens utilize the host inflammatory responses and have a growth advantage over commensals to promote their growth in host tissues.

23Studies show that intestinal inflammation has always been associated with an imbalance of the gut microbiota in IBD patients as well as with experimental colitis models, which is characterized by a reduced diversity and abundance of obligate anaerobic bacteria such as Clostridia or Bacteroidia and an expansion of anaerobic, facultative bacteria such as Proteobacteria and other members of the Enterobacteriaceae. These microbial changes during inflammation might reflect changes in the nutritional landscape of the gut environment, which is created by the host inflammatory responses. By inducing inflammation, the gut physiological environment and the available nutrient profiles are altered, which may lead to the inhibition of commensal bacteria and the proliferation of pathogenic bacteria due to the expression of unique metabolic pathways and virulence genes, which are absent in the commensals. For example, IL-22 is a cytokine abundant during S. Typhimurium infection that correlates with the high level of galactoside 2-α-l-fucosyltransferase 2 that promotes the α(1,2)-fucosylation of mucus carbohydrates, thus altering the level of fucose in the intestine lumen. The liberation of fucose from mucus carbohydrates leads to the activation of fucose-related genes in other members of the gut microbiota such as E. coli. The rising level of the mucus-derived carbohydrate in the gut luminal nutrient content supports the growth of pathogenic bacteria; as a result, the composition of the gut microbiota is altered that may be implicated in disease occurrence. Similarly, during inflammation, the generation of reactive oxygen and nitrogen species and SCFA production alter the intestinal nutrient contents and the physiological environment which support pathogen growth. For example, the proinflammatory cytokine IFN-γ activates the mucosal epithelium dual oxidase 2, which causes the production of hydrogen peroxide. The gene DUOX2 upregulation and their associative enzymes dual oxidase 2 have been found with an expansion of Proteobacteria in the gut microbiota of patients with Crohn’s disease and ulcerative colitis. IFN-γ is also implicated in the expression of the gene Nos2, which leads to the production of the inducible nitric oxide synthase that oxidizes l-arginine into nitric oxide. Therefore, a high level of nitric oxide is present in the intestine of IBD patients. These radical species are transformed into non-toxic compounds such as nitrates and exist in elevated levels in the intestine of mice with colitis that can be used by members of the family Enterobacteriaceae such as E. coli and S. Typhimurium due to the presence of nitrate reductase enzymes, which convert nitrate into an electron receptor in a couple of reaction series, a process termed nitrate respiration, resulting in the expansion of the gut-resident pathobionts and obligate pathogens such as E. coli and S. Typhimurium, respectively. The generation of inflammatory factors during colitis creates a physiological niche in the lumen of the host gut that is enriched with pathogen-specific nutrients, which upregulate the growth of anaerobic facultative bacteria Enterobacteriaceae rather than obligate anaerobes. Consequently, pathogenic bacteria have growth advantages over the gut commensal bacteria population during intestinal inflammation; as a result, the gut microbiota community ecological interactions and microbe–microbe and microbe–host interactions are disturbed, which may be linked to enteric obligate pathogen colonization or resident pathobiont expansion and its associated intestinal infections. The respiratory nutrient-rich niche that results from the host immune-inflammatory responses is, therefore, a battlefield in which the gut bacteria commensals and pathogenic species fight for dominance using the diverse resources of nourishing and antimicrobial approaches.

24The idea of gut microbiota-targeting therapy has been used for years to prevent enteric pathogen infections; however, the lack of knowledge about the underlying mechanism of how commensals mediate colonization resistance and regulate resistance to pathogen colonization hampered the progression in the field. The current advancement in gut microbiome research revealed mechanistic insights into commensal–pathogen interaction, which may help in suggesting additional ways of pathogen prevention and eradication. For example, 16S rRNA and metagenome sequencing provide insights into the taxonomic composition and a detailed genetic capacity of the microbial community in the gut. Similarly, the use of germ-free animal models with emerging technologies, such as transcriptomics and laser-capture microdissection, has enabled the mechanistic associative studies of microbe–microbe and microbe–host interactions. In addition, the emergence of new imaging quantitative technologies has enabled the site-specific microbial community localization and investigation of the complex microbial interaction within the gut and provided a high-resolution image of this complex chemistry landscape of the interactions between microbes and the host, which may facilitate the stage for intentionally informed manipulation of this chemistry with probiotic or prebiotic intervention to treat or prevent pathogen-associated diseases. EPEC and EHEC are the more common diarrhea-genic E. coli strains, responsible for the high rate of morbidity and mortality across the world each year. In the mouse infectious model of C. rodentium, simple sugar that is released from the mucus carbohydrate regulates the ability of the gut microbial commensals such as commensal E. coli to outcompete the enteropathogenic strains of E. coli for the source of energy. The eradication of the EPEC and EHEC may be more efficient with commensal strains if the LEE-encoded virulence factors of the pathogen are targeted during the early stage of infections. This approach may be effective in the eradication of not only the enteropathogens EPEC or EHEC but also other pathogens such as C. difficile and VRE. The overgrowth of C. difficile and VRE has been found as a leading cause of diarrhea and colitis among healthcare-associated infections, and a specific bacterial population has also been recognized with the clearance and eradication of C. difficile and VRE in the gut. Although the underlying mechanism of action is unknown, it may be mediated through a direct mechanism such as competition for the limited sources of nutrients; thus, pathogenic bacteria may outcompete certain commensals having the same source of nutrients and energy. Therefore, the current understanding recommends the manipulation of the gut microbiota with the administration of probiotic strains metabolically related to EPEC or EHEC or prebiotic supplementation that could boost the growth of the gut-resident natural competitors, which may be an effective strategy to prevent these enteric infections. The emerging hybrid technology, metagenomics, and mathematical modeling may inform the development of precision microbiome reconstitution therapy. Notably, the microbial transfer from a healthy donor to infected subjects, termed microbiota transplantation, has proven the efficacy of the gut microbiota-based therapy as an effective treatment approach in C. difficile infection which is refractory to chemotherapy. However, variation in the donor gut microbiota composition and the presence of possible potentially harmful microbes may limit the use of microbiota transplantation in the clinic setting. Therefore, identification and characterization of the gut microbiota-specific commensal species related to eradication and growth inhibition of pathogens are necessary; it may help in the formulation of the more targeted therapy against pathogen infection based on the use of a single commensal species or a combination of commensal species to treat the infection. In addition, understanding the metabolic pathways used by commensal bacteria for the prevention and eradication of pathogenic bacteria will help in the development of next-generation probiotics, where genetically modified commensal strains with enhanced anti-pathogenic capacity will be used to limit pathogen colonization and prevent infections more efficiently.

25In these exciting movements, the progression of multidisciplinary research and the emergence of new technologies provide mechanistic insights into the interplay between the microbiota, host, and pathogens and offer a wide range of translational research opportunities for the biomedical research community to gain a molecular understanding of this cross-talk and transform it into new therapeutics options against infectious diseases.

26The current review of literature studies provides the latest insights into the interaction of microbiota in the gut. The first section particularly focuses on the mechanisms of commensal bacteria by which they mediate pathogen colonization resistance and eradicate pathogens from the gut environment. The second part is about the mechanisms of pathogenic bacteria and how pathogenic bacteria break up this resistance and colonize the gut and cause infections. Studies on the gut microbiota composition along the GIT indicated that their population in the intestine is dictated by nutrient availability, the physiological condition of the gut environment, and the gut microbial interaction within the community and with the host. In a healthy state, there is a delicate balance in the gut microbiota population where the commensals dominate over the pathobionts/pathogens and occupy all niches and nutrients along the intestine and restrain the pathobiont overgrowth and invaded or invading pathogen colonization by having efficient metabolic pathways that outcompete the access of pathogens for the limited nutrient resource in the intestine. Similarly, commensals activate the host immune response against pathogens to prevent their proliferation and change the gut physiological environment such as pH, which prevents pathogen virulence gene expression, which is essential for pathogen colonization. However, any interruption, commonly associated with antibiotic use or diet intervention, of this delicate balance between commensals and pathobionts ultimately results in the loss of commensal-mediated pathogen colonization resistance, which may lead to overpopulation of pathobionts/pathogens. Meanwhile, pathogens use their chemical machinery and express virulent factor genes, induce local inflammation, and convert the gut physiological environment into one that favors their growth and inhibits the commensal population, thus leading to infectious diseases. At present, the microbiome science is relatively quite young; therefore, it warrants further understanding of the gut microbial community interactions to decipher the complex relationship of commensal–pathogen interactions and the gut microbiota–host interactions, which may be helpful in the establishment of rational approaches to manage intestinal infectious diseases. In addition, host immunity has also been implicated in the gut microbiota regulation, in both commensal bacteria and pathogen-mediated inflammation, thus indicating a critical role of immune factors in determining the composition of the gut microbiota. Therefore, it is suggested that additional studies need to be undertaken to clarify the mechanisms on the host side by which they regulate and affect the gut microbiota during the host health and disease.

27IK provided the study concept. CZ and HS provided guidance and resources. IK, YB, LZ, NU, HU, and SS searched and compiled the relevant literature. IK wrote the manuscript. HS reviewed the manuscript. CZ edited the manuscript and conducted the publishing process. The rest of the co-authors contributed equally as per the authorship policy of the article publication in peer review journals. All authors have read the journal policy and agreed to be accountable for all aspects of the work and have given the final approval of the manuscript to be published.

28This work was supported by the Jiangsu Science and Technology Major Project (BA2016036) and the Gansu Science and Technology Major Project (17ZD2FA009).

29The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

30The reviewer MK declared a shared affiliation, though no other collaboration, with the authors.

31All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.